Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer

Educational Objectives

Lung Cancer Incidence and Pathology

Case 1: Introduction

Initial Work-Up for a Patient With Newly Diagnosed Advanced NSCLC

Guidelines for Molecular Testing in Advanced NSCLC

Plasma-Based Molecular Testing

Case 1 (cont)

First-Line Treatment Options for EGFR-Mutated Advanced NSCLC

LUX-Lung 3 and LUX-Lung 6 Patients With del19 EGFR-Mutated NSCLC

LUX-Lung 7: Head-to-Head Trial Gefitinib vs Afatinib in Treatment-Naive Patients With EGFR-Mutated NSCLC

ALK Rearrangement

ALK-Targeting Therapies

J-ALEX: Phase 3 Trial of Alectinib in Front-Line Treatment of ALK+ NSCLC

Case 1 (cont)

Common EGFR TKI Therapy Adverse Events

Management of EGFR TKI Adverse Events

Management of EGFR TKI Adverse Events (cont)

ALK Inhibitor Adverse Events and Management

Case 2: Progression on First-Line EGFR TKI

Osimertinib: Efficacy and Safety

Summary and Concluding Remarks

Abbreviations

Abbreviations (cont)